{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:41:09Z","timestamp":1792813269852,"version":"4.5.0"},"reference-count":68,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1080\/19420862.2020.1854149","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T05:44:14Z","timestamp":1608011054000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":146,"title":["Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline"],"prefix":"10.1080","volume":"12","author":[{"given":"Marco","family":"Tuccori","sequence":"first","affiliation":[{"name":"University Hospital of Pisa","place":["Pisa, Italy"]},{"name":"University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ferraro","sequence":"additional","affiliation":[{"name":"University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Convertino","sequence":"additional","affiliation":[{"name":"University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0386-3816","authenticated-orcid":false,"given":"Emiliano","family":"Cappello","sequence":"additional","affiliation":[{"name":"University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1616-8644","authenticated-orcid":false,"given":"Giulia","family":"Valdiserra","sequence":"additional","affiliation":[{"name":"University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Blandizzi","sequence":"additional","affiliation":[{"name":"University Hospital of Pisa","place":["Pisa, Italy"]},{"name":"University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Maggi","sequence":"additional","affiliation":[{"name":"Varese University Hospital","place":["Varese, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Focosi","sequence":"additional","affiliation":[{"name":"Pisa University Hospital","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00965-w"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03020-3"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218479"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00072-20"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2170"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.09.036"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1768806"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.044"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1796425"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006602.pub4"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.08.009"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbaa020"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y"},{"key":"e_1_3_2_16_1","unstructured":"[no author listed]. Vir biotechnology and GSK start phase 2\/3 study of COVID-19 antibody treatment. GSK website."},{"key":"e_1_3_2_17_1","unstructured":"[no author listed]. VIR-7831 for the early treatment of COVID-19 in outpatients (COMET-ICE). clinicaltrials.gov."},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.11582"},{"key":"e_1_3_2_19_1","unstructured":"Yaragalla S Narang P Kadam KJ Remedios Kimberly C Sahni S Singh A Khan N Yadav S et al. COVID-19 pandemic: a comprehensive updated review with an artificial intelligence (AI). [Accessed 2020 Oct 1]. http:\/\/www.onlinescientificresearch.com\/articles\/covid19-pandemic-a-comprehensive-updated-review-with-an-artificial-intelligence-ai.pdf."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-0732-3"},{"key":"e_1_3_2_21_1","unstructured":"[no author listed]. Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting. Eli Lilly webpage."},{"key":"e_1_3_2_22_1","unstructured":"A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 - Full Text View - ClinicalTrials.gov. [Accessed 2020 Oct 1]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04411628?cond=NCT04411628&draw=2&rank=1."},{"key":"e_1_3_2_23_1","unstructured":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1). clinicaltrials.gov.. [Accessed 2020 Nov 9]."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00138"},{"key":"e_1_3_2_26_1","unstructured":"Bamlanivimab COVID-19 Treatment \u2014 Precision Vaccinations. [Accessed 2020 Nov 4]. https:\/\/www.precisionvaccinations.com\/vaccines\/bamlanivimab-covid-19-treatment."},{"key":"e_1_3_2_27_1","unstructured":"[no author listed]. A study of LY3819253 (LY-CoV555) in preventing SARS-CoV-2 infection and COVID-19 in nursing home residents and staff (BLAZE-2). clinicaltrials.gov."},{"key":"e_1_3_2_28_1","unstructured":"[no author listed]. ACTIV-2: a study for outpatients with COVID-19. clinicaltrials.gov."},{"key":"e_1_3_2_29_1","unstructured":"[no author listed]. ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO). clinicaltrials.gov."},{"key":"e_1_3_2_30_1","unstructured":"Lovelace B Farr C U.S. pauses Eli Lilly\u2019s trial of a coronavirus antibody treatment over safety concerns. CNBC website. Published 2020 [Accessed 2020 Oct 15]. https:\/\/www.cnbc.com\/2020\/10\/13\/us-pauses-eli-lillys-trial-of-a-coronavirus-antibody-treatment-over-safety-concerns.html."},{"key":"e_1_3_2_31_1","unstructured":"[no author listed]. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. FDA Official Website. Published 2020 [Accessed 2020 Nov 10]. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19."},{"key":"e_1_3_2_32_1","unstructured":"[no author listed]. A message from BeiGene regarding our COVID-19 (coronavirus) response. Beigene website."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.025"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M600697200"},{"key":"e_1_3_2_35_1","unstructured":"[no author listed]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody BGB-DXP593 in participants with mild-to-moderate coronavirus disease 2019 (COVID-19). clinicaltrials.gov."},{"key":"e_1_3_2_36_1","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody BGB-DXP593 in participants with mild-to-moderate coronavirus disease 2019 (COVID-19) - full text view - clinicaltrials.gov","author":"Prabakaran P","year":"2006","unstructured":"Prabakaran P, Gan J, Feng Y,\u00a0 Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody BGB-DXP593 in participants with mild-to-moderate coronavirus disease 2019 (COVID-19) - full text view - clinicaltrials.gov. J Biol Chem. 2006. [Accessed 2020 Sep 29]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04551898?term=BGB-DXP593&draw=2&rank=1.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy285"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0827"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831"},{"key":"e_1_3_2_40_1","unstructured":"Safety Tolerability and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19. [Accessed 2020 Oct 4]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04426695?term=REGN-10933&cond=COVID-19&phase=1235&draw=2&rank=2."},{"key":"e_1_3_2_41_1","unstructured":"[no author listed]. Safety tolerability and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for the treatment of ambulatory adult patients with COVID-19. clinicaltrials.gov."},{"key":"e_1_3_2_42_1","unstructured":"[no author listed]. Regeneron\u2019s REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients. Regeneron website."},{"key":"e_1_3_2_43_1","volume-title":"Published online. PRNewswire Oct","author":"Regeneron Pharmaceuticals. Regeneron\u2019 s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention","year":"2020","unstructured":"Regeneron Pharmaceuticals. Regeneron\u2019 s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention. Published online. PRNewswire Oct. 28, 2020 PRNewswire."},{"key":"e_1_3_2_44_1","volume-title":"REGN-COV2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements","author":"Regeneron Pharmaceuticals","year":"2021","unstructured":"Regeneron Pharmaceuticals. REGN-COV2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements. 2021."},{"key":"e_1_3_2_45_1","unstructured":"[no author listed]. Monoclonal antibodies study for prevention of SARS CoV-2 infection in healthy adults who are household contacts to an individual with a positive COVID-19 test. niaid.nih.gov."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3584"},{"key":"e_1_3_2_47_1","unstructured":"[no author listed]. Randomised Evaluation of COVID-19 Therapy (RECOVERY). clinicaltrials.gov."},{"key":"e_1_3_2_48_1","unstructured":"Casirivimab and Imdevimab. https:\/\/www.regeneron.com\/casirivimab-imdevimab. [Accessed November 27 2020]"},{"key":"e_1_3_2_49_1","unstructured":"Celltrion accelerates development of COVID-19 antiviral treatment. [Accessed 2020 Nov 3]. https:\/\/www.celltrionhealthcare.com\/en-us\/board\/newsdetail?modify_key=174&pagenumber=1&keyword=&keyword_type=."},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs\u201359639\/v1"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.012"},{"key":"e_1_3_2_52_1","unstructured":"To Evaluate the Safety Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects - Full Text View - ClinicalTrials.gov. [Accessed 2020 Nov 3]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04525079?term=NCT04525079&draw=2&rank=1."},{"key":"e_1_3_2_53_1","unstructured":"Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59. [Accessed 2020 Nov 3]. https:\/\/www.celltrionhealthcare.com\/en-us\/board\/newsdetail?modify_key=364&keyword=&keyword_type=."},{"key":"e_1_3_2_54_1","unstructured":"This is a Phase 1 Study to Evaluate the Safety Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19) - Full Text View - ClinicalTrials.gov. [Accessed Nov 3]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04593641?term=NCT04593641&draw=2&rank=1."},{"key":"e_1_3_2_55_1","unstructured":"Celltrion receives Korean MFDS approval to initiate Phase I trial of CT-P59 in patients. [Accessed Nov 3]. https:\/\/www.celltrionhealthcare.com\/en-us\/board\/newsdetail?modify_key=353&keyword=&keyword_type=."},{"key":"e_1_3_2_56_1","unstructured":"To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19 - Full Text View - ClinicalTrials.gov. [Accessed 2020 Nov 3]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04602000?term=CT-P59&draw=2&rank=2."},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2381-y"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.37756\/bk.20.2.6.2"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00071"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.28.066977"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9050324"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.12.148726"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.22.20159905"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.08.332544"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.18.20177303"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.09.333278"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048723"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu396"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.14.988345"}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2020.1854149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:00:53Z","timestamp":1762430453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2020.1854149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1080\/19420862.2020.1854149"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2020.1854149","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1854149"}}